

application, a new specification was submitted. This new specification included 22 claims. The Patent Office appears to have examined Claims 1-18 that were pending in the PCT application.

Regardless, Applicants are submitting herewith four additional claims. Two of these claims were submitted with the application as filed and apparently not made of record by the Patent Office. Accordingly, Applicants are submitting herewith newly-submitted Claims 20-24. Support for these claims can be found in the specification. These claims do not add new matter.

Applicants elect, without traverse, Group III (Claims 18 and 19). Newly-submitted Claims 20-24 all relate to this group and therefore are part of the election.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Versions with Markings to Show Changes Made.**"

Respectfully submitted,

BELL, BOYD & LLOYD LLC



Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204



VERSION WITH MARKINGS TO SHOW CHANGES MADE

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

In the Specification:

Please amend the Abstract to delete "Crones" and substitute therefor --Crohn's--.

At page 9 at line 18, please amend "Chrone's" and substitute therefor --Crohn's--.

In the Claims:

Please add newly-submitted Claims 20-24 as follows:

20. A method for the treatment or prevention of Claim 18 wherein the effective amount of a CD14 variant or fragment thereof which retains the bioactivity of CD14 is provided in an infant formula.

21. A method of treatment or prevention of Claim 18 wherein the CD14 variant or fragment includes an isolated protein having no O-glycosylation and an amino acid sequence that is at least 70% homologous with the amino acid sequence of human serum CD14.

22. A method of treatment or prevention of Claim 18 including the step of administering a composition including a protein that does not include o-glycolation and has an amino acid sequence that is at least 70% homologous with human serum CD14.

23. A method of treatment according to Claim 20 wherein the GI tract disorder is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ulcerative colitis, coeliac disease, intestinal bacterial overgrowth, chronic hepatitis, necrotising enterocolitis, neonatal sepsis, infectious diarrhoea, disbalance of the intestinal microflora, allergic reactions to food and bacterial translocation from the gut to other compartments of the body.

24. A method of treatment of Claim 18 wherein the effective amount of a CD14 variant or fragment thereof which retains the bioactivity of CD14 is administered to an infant.